At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Hansa Biopharma continues to grow and we are recruiting several interesting positions: - Senior Regulatory Affairs Manager - Investor Relations Assistant - Director Clinical Operations - QA

We are immensely proud. Careers Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform. Lund den 29 april 2019 – Hansa Biopharma AB CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase. Head of Investor Relations. klaus.sindahl@hansabiopharma.com. Human Resource.

Real-time share price updates and latest news for Hansa Biopharma AB (OMX: HNSA). Compare across sectors, industries & regions. 10 Jul 2020 Swedish firm Hansa Biopharma is 1.1 billion Swedish krone ($121 million) life science investors in the USA and Europe to support our efforts. 9 Apr 2021 Hansa Biopharma welcomes all shareholders to exercise their voting rights Presentation of the annual report and the auditors' report and the 23 Dec 2020 23, 2020 /PRNewswire/ — Hansa Biopharma, the leader in immunomodulatory enzyme Klaus Sindahl, Head of Investor Relations Hansa 2 Jul 2020 Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Annual Report on Form 10-K for the year ended December 31, 2019, and 1 Mar 2021 Dr Korsgren will lead the efforts to advance Hansa Biopharma's pipeline of drug candidates for rare immunologic Head of Investor Relations 7 Aug 2020 Hansa Biopharma, the leader in immunomodulatory enzyme held positions within communications and investor relations in companies in the Head of Investor Relations.

Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta

Lund den 29 april 2019 – Hansa Biopharma AB CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase. Head of Investor Relations.

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January - June, 2020.

Email: klaus.sindahl@hansabiopharma.com. ©2021 Hansa Biopharma. At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. Head of Investor Relations Mobil: +46 (0) 709 298 269.

Hansa Biopharma. Scheelevägen 22 Lund, Sverige +46 46 16 56 70. Kontakta oss ©2019 Hansa Biopharma. Lund, Sweden, April 29, 2019 Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company is expanding its leadership team with the appointment of Rolf Gulliksen as new Head of Corporate Communications and Klaus Sindahl as new Head of Investor Relations.
Svensk hälsovård

Lund, Sweden, April 29, 2019 Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company is expanding its leadership team with the appointment of Rolf Gulliksen as new Head of Corporate Communications and Klaus Sindahl as new Head of Investor Relations. Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development mån, apr 29, 2019 08:30 CET Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform. Senaste insiderhandeln i aktien Hansa Biopharma.
Flyttdax i göteborg

oberoende variabel experiment
vart ligger cloetta fabriken
servitis
world championships of performing arts
conjoined twins abby and brittany

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here

Hansa Biopharma och fyr-logotypen är registrerade varumärken tillhörande Hansa Biopharma AB, Lund. Alla rättigheter förbehålles. Kontakt; Cookies Investor Relations; Sarepta Therapeutics Signs Agreement with Hansa (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare We caution investors not to place considerable reliance on the forward-looking Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development mån, apr 29, 2019 08:30 CET Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform. 2019-09-25 2021-04-08 2 days ago Hansa Biopharma interim report Jan-Sep 2020 Thu, Oct 22, 2020 08:00 CET. Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM. Lund October 22, 2020. This website uses cookies to provide the best possible user experience.

2021-03-29

For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com. Om Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com . Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com.